Ironwood Pharmaceuticals

Ironwood Pharmaceuticals

Biotechnology
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.

$689.1M

Market Cap • 9/14/2026

1998

(28 years)

Founded

2010

(16 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

P/S

1,8

P/EBITDA

2,9

P/OCF

3,7

P/FCF

3,7

P/E

5,4

BVPS

EPS

0,8

Market Cap

Market Cap

689,1M

EV

1B

EV/Revenue

2,6

EV/EBITDA

4,3

EV/EBIT

4,3

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-0,1%

Total Yield

-0,1%

Payout

0%

Retained Earnings

-1,6B

Profitability

Gross Margin

100%

EBITDA Margin

60,6%

EBIT Margin

60,1%

Net Margin

73,2%

D&A/EBITDA

0%

R&D/Revenue

22,8%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

7,7%

% PPE

4%

% Goodwill

0%

ROE

ROIC

182,3%

Growth

CAGR Revenue 5Y

-1,2%

CAGR Op. Income 5Y

2,4%

CAGR EPS 5Y

-24,4%

CAGR OCF 5Y

-4%

Leverage

N.D./EBITDA

1,3

Debt/Equity

0%

Current Ratio

6,1

Quick Ratio

5,8

Interest Coverage

716,9%

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium